| Document Date: 2014-02-18 05:51:30
Open Document File Size: 94,06 KBShare Result on Facebook
City Barcelona / Barcelona Valbonne / / Company Andrew Lloyd & Associates / TxCell SA / / Country France / / / Event FDA Phase / / Facility National Institute / / / IndustryTerm treatment of severe chronic inflammatory diseases / biotechnology company developing cell-based immunotherapies / food antigen / treatment of inflammatory bowel diseases / technology park / / MedicalCondition disease / severe chronic inflammatory diseases / refractory rheumatoid arthritis / inflammatory bowel diseases / inflammation / chronic active Crohn's disease / severe chronic active Crohn / / MedicalTreatment immunotherapies / immunotherapy / / Organization CONTACTS TxCell Business Development Department / National Institute for Health and Medical Research / Colitis Organization / / Person Arnaud Foussat / Vicky Leek / François Meyer / Sophia Antipolis / / / Position chief scientific officer / chief executive officer / / Product Crohn / France / Ovasave® / / Region southern France / / Technology biotechnology / / URL www.txcell.com / /
SocialTag |
TxCell presents immuno-monitoring results of its Phase I/II clinical trial with antigen-specific Treg cells in Crohn’s disease Results supportive of Ovasave® mechanism of action were presented at the 7th European Croh